CD19-CAR-T2 cell therapy (Nanfang Hospital of Southern Medical University)

N/A

Report date: 2022/05/25 17:50:45

Base Information

Drug NameCD19-CAR-T2 cell therapy (Nanfang Hospital of Southern Medical University)
Drug Alias NameCD19-CAR-T2 cells (广东省人民医院)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLeukemia, Biphenotypic, AcuteLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanfang Hospital Of Southern Medical University
China Registration ClassN/A

Develop Information

Active CompaniesNanfang Hospital Of Southern Medical University
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLeukemia, Biphenotypic, AcuteLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A